Mandate

Vinge has advised SEB in connection with an issue of additional Tier 1 captial of MUSD 600

Vinge has advised Skandinaviska Enskilda Banken AB (publ) (“SEB”) as to Swedish law in connection with the bank’s issue of Additional Tier 1 Capital in the amount of MUSD 600 in the form of a debt instrument with no final maturity and with automatically conversion into Class A-shares if the CET1 ratio of the bank decreases to a certain level.

The instrument is listed on the Global Exchange Market regulated by the Irish Stock Exchange.

SEB issued the Additional Tier 1 Capital to refinance an old similar instrument that reaches its call date later this year and to optimize its capital structure.

Vinge’s team consisted mainly of Göran Nyström, Charlotte Levin, Albert Wållgren and Malte Hedlund.

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026